[CAS NO. 1798286-48-2] Camrelizumab

Ships within

Stock

Price

Qty

Total

$0.00

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1798286-48-2]

Catalog

HY-P9971

Brand

MCE

CAS

1798286-48-2

DESCRIPTION [1798286-48-2]

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Camrelizumab]

For research use only. We do not sell to patients.

1 Publications Citing Use of MCE

[1]Front Oncol. 2022 Jul 28;12:960066.

Summary

Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1 . Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC ₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al ^[1] ^[2] .

IC50 & Target

IC50: 0.70 nM ( PD-1/PD-L1 interaction) ^[1]

In Vitro

In a T cell proliferation assay using tuberculin treated peripheral blood mononuclear cells, Camrelizumab induces a T cell proliferation at an EC ₅₀ of 0.11 nM. In a similar assay measuring IFN-gamma secretion, Camrelizumab induces IFN-gamma production at an EC ₅₀ of 0.38 nM ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Camrelizumab (3 mg/kg) combines with apatinib (200 and 100 mg/kg) inhibits the tumor inhibition rates reached 63.1% and 87.3%, respectively in human PD-1 transgenic mice ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03603756	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Esophageal Squamous Cell Carcinoma	July 31, 2018	Phase 2
NCT05387512	Affiliated Hospital of Nantong University\|The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China	Lung Cancer	January 12, 2022
NCT05313282	Sun Yat-sen University\|Jiangsu HengRui Medicine Co., Ltd.	C-staged Hepatocellular Carcinoma in BCLC Classification	June 15, 2022	Phase 3
NCT04878107	Wuhan University	Non-Small Cell Lung Cancer	March 15, 2022	Phase 2
NCT04670913	Junling Li\|Peking Union Medical College	Advanced Non Squamous NSCLC	June 28, 2021	Phase 2
NCT05050760	Xijing Hospital	ESCC	September 1, 2021	Not Applicable
NCT04910126	Wuhan Union Hospital, China	Soft Tissue Sarcoma\|Neoplasms, Connective and Soft Tissue\|Sarcoma Metastatic\|Sarcoma,Soft Tissue	November 12, 2020	Phase 2
NCT04559607	Zhongda Hospital	Hepatocellular Carcinoma	September 11, 2020	Not Applicable
NCT04514081	Chinese PLA General Hospital	Hodgkin Lymphoma\|Anti-PD-1 Antibody Resistant	August 1, 2020	Phase 2
NCT05265793	Fudan University	PD-1 Immunotherapy\|VEGFR-TKI\|Sarcomatoid Carcinoma\|Carcinosarcoma	November 21, 2021	Phase 2
NCT04483284	Shanghai Zhongshan Hospital	Hepatocellular Carcinoma	June 24, 2020	Phase 2
NCT04233294	Chinese PLA General Hospital	Hodgkin Lymphoma	February 2, 2020	Phase 2
NCT04338620	Tang-Du Hospital	Non-small-cell Lung Cancer (NSCLC)	March 12, 2020	Phase 2
NCT04294784	Huazhong University of Science and Technology	Gastric Cancer\|GastroEsophageal Cancer	April 3, 2020	Phase 2
NCT04426955	Jiangsu HengRui Medicine Co., Ltd.	Esophageal Cancer	June 30, 2020	Phase 3
NCT04191889	Sun Yat-sen University\|Jiangsu HengRui Medicine Co., Ltd.	C-staged Hepatocellular Carcinoma in BCLC Classification	April 13, 2020	Phase 2
NCT04070040	Beijing Sanbo Brain Hospital	Primary Central Nervous System Lymphoma	February 13, 2020	Phase 2
NCT03817658	The First Affiliated Hospital of Zhengzhou University\|Jiangsu HengRui Medicine Co., Ltd.	Esophageal Squamous Cell Carcinoma	October 2019	Phase 2
NCT05476380	Tianjin Medical University Cancer Institute and Hospital	Esophageal Carcinoma	February 19, 2021	Phase 2
NCT04523662	Beijing Tsinghua Chang Gung Hospital	Hepatocellular Carcinoma	August 30, 2020	Phase 2
NCT04901754	Henan Cancer Hospital	Small Cell Lung Carcinoma	July 14, 2021	Phase 2
NCT04298320	Yanqiao Zhang\|Harbin Medical University	Colorectal Cancer	March 15, 2020	Phase 1\|Phase 2
NCT03939962	Henan Cancer Hospital	Gastric Cancer	July 24, 2019	Phase 2
NCT05559008	Ruijin Hospital	Peripheral T Cell Lymphoma	September 30, 2022	Phase 1\|Phase 2
NCT04861467	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	HNSCC	June 1, 2021	Phase 2
NCT05339581	RenJi Hospital	Liver Cancer\|Liver Transplant; Complications\|Hepatocellular Carcinoma\|Portal Vein Thrombosis\|Radiotherapy; Complications	May 20, 2022	Not Applicable
NCT04520035	Fudan University	PFS	August 1, 2020	Phase 2
NCT05320081	Huazhong University of Science and Technology\|The First Affiliated Hospital of Nanchang University	Lymphoma\|Relapse+Recurrence	November 30, 2021	Phase 2
NCT05236699	Tongji Hospital	Intrahepatic Cholangiocarcinoma	February 1, 2022	Phase 2
NCT03346642	Chinese PLA General Hospital	Primary Mediastinal Large B-cell Lymphoma	May 1, 2017	Phase 1\|Phase 2
NCT04507750	Qianfoshan Hospital\|Jiangsu Hengrui Pharmaceutical Co., Ltd.	Immune Checkpoint Inhibition	August 10, 2020	Not Applicable
NCT04345783	Beijing Friendship Hospital	Gastric Cancer	January 1, 2018	Phase 2
NCT04848454	Peking University First Hospital	HER2-negative Breast Cancer\|Neoadjuvant Therapy\|Pathological Complete Response\|Immunotherapy\|Vinorelbine\|Cisplatin	November 20, 2021	Phase 2
NCT04340401	Peking University Cancer Hospital & Institute	Rectal Cancer	May 25, 2020	Phase 2
NCT05005468	Shanghai Chest Hospital	NSCLC	September 2021	Phase 2
NCT05490485	Henan Cancer Hospital	Squamous Cell Carcinoma of the Skin	August 5, 2022	Phase 2
NCT05222035	Sun Yat-sen University	PD-1 Inhibitor\|G-CSF	January 24, 2022	Phase 2
NCT04425135	The First Affiliated Hospital of Xiamen University	Lung Neoplasms	July 2020	Phase 2
NCT04928807	Wuhan Union Hospital, China\|Jiangsu HengRui Medicine Co., Ltd.	Rectal Cancer	July 20, 2021	Phase 3
NCT03766178	The First Affiliated Hospital of Zhengzhou University	Esophageal Squamous Cell Carcinoma	September 2021	Phase 2
NCT04639180	Jiangsu HengRui Medicine Co., Ltd.	Hepatocellular Carcinoma (HCC)	April 1, 2021	Phase 3
NCT03394287	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Breast Cancer	January 10, 2018	Phase 2
NCT03200691	Hangzhou Cancer Hospital\|Jiangsu HengRui Medicine Co., Ltd.	Esophageal Neoplasms\|Esophageal Diseases	August 10, 2017	Phase 2
NCT04342936	Jiangsu HengRui Medicine Co., Ltd.	Classical Hodgkin Lymphoma	July 17, 2020	Phase 3
NCT05385185	Hebei Medical University	Leptomeningeal Metastasis\|Immune Checkpoint Inhibitor\|Endostatin	May 1, 2022	Phase 2
NCT03121716	Jiangsu HengRui Medicine Co., Ltd.	Nasopharyngeal Carcinoma	April 26, 2017	Phase 1
NCT05142865	Huazhong University of Science and Technology	Advanced or Metastatic EP-NEC	January 14, 2022	Phase 2
NCT04572542	The First Affiliated Hospital of Xiamen University	Locally Advanced or Metastatic Gastric Adenocarcinoma	January 1, 2020	Phase 1\|Phase 2
NCT03222440	Tianjin Medical University Cancer Institute and Hospital\|Jiangsu HengRui Medicine Co., Ltd.	Esophageal Cancer	July 19, 2017	Not Applicable
NCT04510610	Chinese PLA General Hospital	Hodgkin Lymphoma	September 1, 2019	Phase 2\|Phase 3
NCT04547088	Sun Yat-sen University	Nasopharyngeal Carcinoma	September 2020	Phase 2
NCT04888806	Harbin Medical University	Colorectal Cancer Metastatic\|Liver Metastases\|Lung Metastases	June 1, 2021	Phase 2
NCT03645876	Jiangsu HengRui Medicine Co., Ltd.	Metastatic Colorectal Cancer	November 8, 2018	Phase 2
NCT05355168	Anhui Provincial Hospital	Toxicity, Drug	November 1, 2021	Phase 1\|Phase 2
NCT03472365	Jiangsu HengRui Medicine Co., Ltd.	Gastric Cancer\|GastroEsophageal Cancer	April 2, 2018	Phase 2
NCT04102982	Shandong Provincial Hospital	NSCLC Stage IV	November 1, 2019	Phase 2
NCT04479527	Peking University Cancer Hospital & Institute\|Jiangsu Hengrui Pharmaceutical Co., Ltd.	Hepatocellular Carcinoma	April 2021	Phase 2
NCT04907344	Tianjin Medical University Cancer Institute and Hospital\|Jiangsu HengRui Medicine Co., Ltd.	Triple Negative Breast Cancer	June 15, 2021	Phase 2\|Phase 3
NCT05461235	China Medical University, China	PD-1 Antibody\|DC-Cell\|NK-Cell\|Gastrointestinal Tumours	July 15, 2022	Phase 2
NCT05139095	Peking Union Medical College Hospital\|Jiangsu HengRui Medicine Co., Ltd.	Gestational Trophoblastic Neoplasia	January 27, 2022	Phase 2
NCT05049681	Feng Wang\|The First Affiliated Hospital of Zhengzhou University	Esophageal Cancer	December 5, 2021	Phase 3
NCT04129996	Fudan University	Triple-Negative Breast Cancer	October 1, 2019	Phase 2
NCT05156970	Shanghai Ninth People´s Hospital Affiliated to Shanghai Jiao Tong University	Recurrent Head and Neck Squamous Cell Carcinoma\|Metastatic Head and Neck Squamous Cell Carcinoma	June 24, 2021	Phase 2
NCT05547737	Henan Cancer Hospital\|Jiangsu HengRui Medicine Co., Ltd.	NSCLC	September 21, 2022
NCT04866862	The First Affiliated Hospital with Nanjing Medical University	Colorectal Neoplasm	April 26, 2021	Phase 2
NCT03182673	Jiangsu HengRui Medicine Co., Ltd.	Solid Tumor	July 24, 2017	Phase 1
NCT04351308	Peking University People´s Hospital\|Chinese Sarcoma Study Group	Osteosarcoma\|Survival\|Chemotherapy Effect\|Toxicity, Drug	May 1, 2020	Phase 2
NCT05330065	The First Affiliated Hospital of Zhengzhou University	Malignant Pleural Effusion	August 1, 2022	Phase 1\|Phase 2
NCT04583020	Peking Union Medical College Hospital\|Jiangsu HengRui Medicine Co., Ltd.	Glioblastoma	November 12, 2020	Phase 2
NCT04701060	Tianjin Medical University Cancer Institute and Hospital	Resectable Hepatocellular Carcinoma	January 26, 2021	Phase 2
NCT05613478	The First Affiliated Hospital with Nanjing Medical University\|Jiangsu Hengrui Pharmaceutical Co., Ltd.	Hepatocellular Carcinoma\|Immunotherapy\|Preoperative	November 2022	Phase 3
NCT05070598	Shengjing Hospital	HER2-positive Gastric Cancer	September 7, 2021	Phase 2
NCT04944914	Sun Yat-sen University\|Affiliated Cancer Hospital & Institute of Guangzhou Medical University\|Zhongshan People´s Hospital, Guangdong, China\|Guangdong Provincial People´s Hospital	Nasopharyngeal Carcinoma	June 1, 2021	Phase 3
NCT04792515	First Affiliated Hospital Xi´an Jiaotong University\|Jiangsu HengRui Medicine Co., Ltd.	Locally Advanced Gastric Cancer	January 1, 2021	Phase 2
NCT03417895	Jiangsu HengRui Medicine Co., Ltd.	Small-cell Lung Cancer	April 20, 2018	Phase 2
NCT05062837	Guangxi Medical University\|Jiangsu HengRui Medicine Co., Ltd.	Hepatocellular Carcinoma	June 1, 2021	Phase 2\|Phase 3
NCT04211090	Sun Yat-sen University\|Jiangsu HengRui Medicine Co., Ltd.	Non-squamous Non-small-cell Lung Cancer\|Brain Metastases	January 15, 2020	Phase 2
NCT04167774	Sun Yat-sen University\|Jiangsu HengRui Medicine Co., Ltd.	Non-Small Cell Lung Cancer	July 30, 2019	Phase 2
NCT04476459	Huiqiang Huang\|Sun Yat-sen University	Diffuse Large B Cell Lymphoma\|High-grade B-cell Lymphoma\|Follicular Lymphoma Grade IIIb\|Transformed Lymphoma\|EBV-Positive DLBCL, Nos\|ALK-Positive Anaplastic Large Cell Lymphoma	July 23, 2020	Phase 1\|Phase 2
NCT05311566	Lei Li\|Peking Union Medical College Hospital	Cervical Carcinoma\|Chemoradiotherapy\|Anti-programmed Cell Death Receptor 1\|Immunotherapy\|Immune Checkpoint Inhibitor\|Survival Outcomes\|Adverse Events\|Early Stage Cervical Cancer\|Locally Advanced Cervical Cancer	March 27, 2022	Phase 2
NCT05472467	Sichuan Cancer Hospital and Research Institute	Non-small Cell Lung Cancer Metastatic	December 21, 2021	Phase 2
NCT04676997	Shandong Cancer Hospital and Institute\|Jiangsu HengRui Medicine Co., Ltd.	Triple Negative Breast Cancer	May 20, 2020	Phase 2
NCT05582499	Fudan University	Breast Neoplasm\|Breast Cancer\|Breast Tumors\|Triple-Negative Breast Cancer (TNBC)\|HER2-positive Breast Cancer\|HER2-negative Breast Cancer\|Hormone Receptor Positive Tumor\|Hormone Receptor Negative Tumor\|Early-stage Breast Cancer\|Locally Advanced Breast Cancer	October 2022	Phase 1\|Phase 2
NCT05600998	Peking University Third Hospital	Ovarian Clear Cell Carcinoma	October 30, 2022	Not Applicable
NCT03359018	Peking University People´s Hospital\|Jiangsu HengRui Medicine Co., Ltd.	Progression-free Survival\|Overall Survival\|Clinical Benefit Rate\|Toxicity	January 1, 2018	Phase 2
NCT05624099	Fujian Cancer Hospital	Esophageal Neoplasms\|Esophageal Diseases\|Digestive System Neoplasms	December 1, 2022	Phase 2
NCT04294511	Sun Yat-sen University\|Jiangsu HengRui Medicine Co., Ltd.	Osteosarcoma	December 26, 2019	Phase 2
NCT04606108	Sun Yat-sen University\|Jiangsu HengRui Medicine Co., Ltd.	Soft Tissue Sarcoma	October 19, 2020	Phase 2
NCT04453826	Sun Yat-sen University\|Affiliated Cancer Hospital & Institute of Guangzhou Medical University\|Zhongshan People´s Hospital, Guangdong, China\|Yuebei People´s Hospital\|Wuzhou Red Cross Hospital\|Fifth Affiliated Hospital, Sun Yat-Sen University	Nasopharyngeal Cancer\|Chemotherapy\|Radiotherapy\|PD-1 Therapy	September 1, 2020	Phase 3
NCT04793139	Guangdong Association of Clinical Trials	Non-small Cell Lung Cancer	April 1, 2021
NCT04888611	Huashan Hospital\|Jiangsu HengRui Medicine Co., Ltd.\|Shanghai Sunstem Biotechnology Co., Ltd.	Recurrent Glioblastoma	October 26, 2021	Phase 2
NCT04035876	Zhejiang University\|Shulan (Hangzhou) Hospital\|West China Hospital\|Huashan Hospital\|Third Affiliated Hospital, Sun Yat-Sen University\|The First Affiliated Hospital of Zhengzhou University\|The First Hospital of Jilin University\|Tianjin First Central Hospital\|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Hepatocellular Carcinoma\|Liver Transplant	July 16, 2019	Phase 1\|Phase 2
NCT05189483	Henan Cancer Hospital	Soft Tissue Sarcoma	January 1, 2022	Phase 2
NCT05097209	Wei Jiang\|Wuzhou Red Cross Hospital\|Guangxi Nanxishan Hospital\|Laibin People´s Hospital\|Lingshan people´s Hospital\|Guilin Medical University, China	Nasopharyngeal Carcinoma	November 1, 2021	Phase 3
NCT03527251	Sun Yat-sen University	Non Small Cell Lung Cancer	May 15, 2018	Phase 1
NCT04318730	West China Hospital	Adrenocortical Carcinoma	April 1, 2020	Phase 2
NCT05198609	Sun Yat-sen University	Hepatocellular Carcinoma	January 17, 2022	Phase 3
NCT04625894	Fudan University	Oligometastatic Gastrointestinal Cancer	December 2020	Phase 1
NCT05151549	Hunan Cancer Hospital\|Jiangsu HengRui Medicine Co., Ltd.	Cervical Cancer	December 1, 2021	Phase 2
NCT05183958	Zhejiang Cancer Hospital\|Zhejiang Provincial People´s Hospital\|The First Affiliated Hospital of Wenzhou Medical Univercity\|Jinhua Municipal Central Hospital Medical Group\|Lishui Municipal Central Hospital\|The Affiliated People´s hospital of Ningbo Univercity\|Huizhou Municipal Central Hospital\|People´s Hospital of Quzhou\|Sun Yet-sen Cancer Center	Esophageal Cancer	December 31, 2021	Phase 2
NCT04353479	Shanghai Jiao Tong University School of Medicine	Acute Myeloid Leukemia	April 25, 2020	Phase 2
NCT04930315	Zhejiang University	Hepatocellular Carcinoma	September 15, 2021	Phase 2
NCT04201990	ShiYue Li\|Guangzhou Institute of Respiratory Disease	Lung Cancer	December 2019	Phase 1\|Phase 2
NCT03755440	Sun Yat-sen University	Gastric Cancer Stage IV\|EBV	December 1, 2018	Phase 2
NCT05611463	Shanghai Ninth People´s Hospital Affiliated to Shanghai Jiao Tong University	Oral Squamous Cell Carcinoma	June 2, 2020	Phase 2
NCT04133337	Sichuan Cancer Hospital and Research Institute\|Jiangsu HengRui Medicine Co., Ltd.	Lung Diseases\|Neoplasms\|Respiratory Tract Diseases\|Thoracic Neoplasms\|Non-small-cell Lung Cancer	November 1, 2019	Phase 1\|Phase 2
NCT04067986	Zhongshan Hospital Xiamen University	Colorectal Cancer Recurrent	August 20, 2019	Phase 1\|Phase 2
NCT04459078	Hunan Cancer Hospital\|Suzhou Sheng Diya Biomedical Co., Ltd.	Adenocarcinoma of the Lung	July 15, 2020	Phase 2
NCT04984018	The First Affiliated Hospital of Zhengzhou University	Esophageal Squamous Cell Carcinoma	December 1, 2021	Phase 2
NCT05447702	West China Hospital\|Jiangsu HengRui Medicine Co., Ltd.	Triple Negative Breast Cancer	July 10, 2022	Phase 2
NCT05380986	Henan Cancer Hospital	Solid Tumor	May 20, 2022	Not Applicable
NCT04826406	Hunan Cancer Hospital\|Jiangsu Hengrui Pharmaceuticals Co.,Ltd	Hepatocellular Carcinoma\|Immune Checkpoint Inhibitors	February 3, 2021	Phase 2
NCT04828395	Tianjin Medical University Cancer Institute and Hospital	Non-small Cell Lung Cancer	March 1, 2021	Phase 2
NCT02942329	The Affiliated Hospital of the Chinese Academy of Military Medical Sciences	Gastric Cancer\|Hepatocellular Carcinoma	October 2016	Phase 1\|Phase 2
NCT05135364	Yue Han\|Jiangsu HengRui Medicine Co., Ltd.\|Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Unresectable Hepatocellular Carcinoma	November 5, 2021	Phase 2
NCT05111444	Fudan University	Gastric Neoplasms\|Gastroesophageal Junction Adenocarcinoma	December 31, 2021	Phase 2
NCT04390945	The First Affiliated Hospital of Henan University of Science and Technology	Esophageal Cancer	December 1, 2021	Phase 2
NCT04047017	Peking Union Medical College Hospital	Gestational Trophoblastic Disease	August 8, 2019	Phase 2
NCT04803539	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University\|Jiangsu HengRui Medicine Co., Ltd.	Breast Cancer	April 1, 2021	Phase 2\|Phase 3
NCT04948125	Henan Cancer Hospital	Advanced Gastric Carcinoma	April 28, 2021	Phase 2
NCT04188860	Lei Li\|Peking Union Medical College Hospital	Recurrent Cervical Carcinoma\|Persistent Advanced Cervical Carcinoma\|Chemotherapy\|Anti-PD-1 Antibody\|Immunotherapy	December 6, 2019	Phase 2
NCT04884906	Tianjin Medical University Cancer Institute and Hospital	Locally Advanced Cervical Cancer	November 1, 2020	Phase 2
NCT05106335	Jiangsu HengRui Medicine Co., Ltd.	Advanced NSCLC	January 6, 2022	Phase 3
NCT05225844	Harbin Medical University	Gastrointestinal Cancer\|Immunotherapy\|Targeted Therapy	January 1, 2019	Phase 2
NCT04947956	Shanghai Zhongshan Hospital	Unresectable Hepatocellular Carcinoma	September 1, 2021
NCT03722875	Shanghai Zhongshan Hospital	Hepatocellular Carcinoma	December 1, 2018	Not Applicable
NCT05602935	The Second Affiliated Hospital of Fujian Medical University	Stomach Neoplasms\|Digestive System Neoplasms\|Neoplasms\|Digestive System Diseases\|Stomach Diseases\|Neoplasms by Site	June 1, 2020	Phase 2
NCT04379739	Shanghai Pulmonary Hospital, Shanghai, China	Non Small Cell Lung Cancer	July 26, 2020	Phase 2
NCT02989922	Jiangsu HengRui Medicine Co., Ltd.	Hepatocellular Carcinoma Non-Resectable	November 2016	Phase 2
NCT04741490	Fuzhou General Hospital	Esophageal Squamous Cell Carcinomas	February 2021	Not Applicable
NCT05097248	Wuhan Union Hospital, China\|Jiangsu HengRui Medicine Co., Ltd.\|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Breast Cancer	October 2021	Phase 2
NCT05367687	Jiangsu HengRui Medicine Co., Ltd.	Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation	June 10, 2022	Phase 2
NCT03099382	Jiangsu HengRui Medicine Co., Ltd.	Esophageal Carcinoma	May 10, 2017	Phase 3
NCT04613674	Jiangsu HengRui Medicine Co., Ltd.	Triple Negative Breast Cancer	December 9, 2020	Phase 3
NCT04397770	Peking University Cancer Hospital & Institute	Melanoma	May 2020	Phase 2
NCT04706598	Fudan University\|Shanghai Shen Kang Hospital Development Center	Urinary Bladder Neoplasms\|Immunotherapy	June 9, 2021	Phase 1\|Phase 2
NCT04393506	Shanghai Jiao Tong University School of Medicine	Oral Cancer\|VEGFR2 Inhibitor\|Programmed Cell Death 1 Inhibitor\|Inductive Therapy	April 23, 2020	Phase 1
NCT04521153	Shanghai Zhongshan Hospital	Hepatocellular Carcinoma\|Immunotherapy\|Molecular Targeted Therapy	March 25, 2021	Not Applicable
NCT04295317	Shanghai Zhongshan Hospital	Intrahepatic Cholangiocarcinoma	August 1, 2020	Phase 2
NCT04533490	The First Affiliated Hospital of Zhengzhou University	Resectable Esophageal Squamous Cell Carcinoma	October 1, 2021	Phase 2
NCT04978012	Fudan University	Nasopharyngeal Carcinoma\|Nasopharyngeal Cancer	July 25, 2021	Phase 2
NCT04979585	Di Wu\|The First Hospital of Jilin University	Melanoma	July 15, 2021	Phase 2
NCT05031949	Zhang Bi Xiang, MD\|Tongji Hospital	Combinational Immunotherapy\|Hepatocellular Carcinoma Non-Resectable\|Hyperbaric Oxygen Therapy	October 30, 2021	Phase 1
NCT03813784	Jiangsu HengRui Medicine Co., Ltd.	Gastric Cancer\|GastroEsophageal Cancer	March 7, 2019	Phase 3
NCT05532527	Henan Provincial People´s Hospital	Nsclc	September 20, 2022	Not Applicable
NCT04782089	Qilu Hospital of Shandong University\|Jiangsu HengRui Medicine Co., Ltd.	Small Cell Lung Cancer	May 6, 2021	Not Applicable
NCT05524168	Sun Yat-sen University\|Shenzhen People´s Hospital\|First People´s Hospital of Foshan\|Jiangxi Provincial Cancer Hospital\|The First Affiliated Hospital of Xiamen University\|Chongqing University Cancer Hospital	Nasopharyngeal Carcinoma	November 2022	Phase 2
NCT05011227	Eye & ENT Hospital of Fudan University\|Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Recurrent Nasopharyngeal Carcinoma	August 10, 2021	Phase 2
NCT04612894	Fudan University	Thyroid Cancer	December 1, 2020	Phase 2
NCT04286958	Hebei Medical University Fourth Hospital	Esophageal Cancer	April 22, 2020	Phase 2
NCT03950271	Henan Cancer Hospital	Gastric Cancer	January 21, 2020	Phase 2
NCT04208347	Ruijin Hospital	Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma	December 18, 2019	Phase 2\|Phase 3
NCT05213884	Chongqing University Cancer Hospital	Head and Neck Squamous Cell Carcinoma	January 1, 2022	Phase 2
NCT05583383	Henan Cancer Hospital	Advanced Gastric Adenocarcinoma	March 31, 2022	Not Applicable
NCT03707509	Jiangsu HengRui Medicine Co., Ltd.	Nasopharyngeal Carcinoma	November 13, 2018	Phase 3
NCT04768075	Guangdong Association of Clinical Trials	Non-Small-Cell Lung Cancer	March 5, 2021	Phase 3
NCT04539600	Sun Yat-sen University	Hypopharyngeal Cancer\|Immunotherapy\|Induction Chemotherapy	November 1, 2020	Phase 2
NCT02721589	Jiangsu HengRui Medicine Co., Ltd.	Lung Cancer	April 6, 2016	Phase 1
NCT05095636	Fudan University	Gastric Cancer\|Metastasis	March 17, 2021	Phase 2
NCT04143984	Shanghai Proton and Heavy Ion Center	Nasopharyngeal Carcinoma	January 19, 2021	Phase 2
NCT05218889	Chinese PLA General Hospital	Pancreatic Cancer\|PDAC - Pancreatic Ductal Adenocarcinoma\|Pancreas Cancer\|Pancreatic Neoplasms	August 4, 2021	Phase 1\|Phase 2
NCT04832204	Beijing Hospital\|Chinese Society of Clinical Oncology	Solid Tumor	March 25, 2021	Phase 2
NCT03558191	Jiangsu HengRui Medicine Co., Ltd.	Nasopharyngeal Carcinoma	August 14, 2018	Phase 2
NCT04631146	Guangdong Association of Clinical Trials	Non-small Cell Lung Cancer	November 30, 2020
NCT03668496	Jiangsu HengRui Medicine Co., Ltd.	Lung Cancer Squamous Cell\|Lung Cancer Stage IV\|PD-1 Antibody\|Chemotherapy Effect	November 9, 2018	Phase 3
NCT04771715	Peking Union Medical College Hospital	Advanced Colorectal Carcinoma	May 1, 2019
NCT04195828	Fujian Medical University	Advanced Gastric Cancer	June 18, 2020	Phase 2
NCT03171220	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Advanced Malignant Solid Tumor	June 1, 2017	Phase 1\|Phase 2
NCT04720131	Beijing Friendship Hospital	Biliary Tract Cancer\|Programmed Cell Death 1 Ligand 1 Gene Mutation\|Targeted Molecular Therapy\|Capecitabine	February 1, 2021	Phase 2
NCT05093140	Sun Yat-sen University\|Jiangsu HengRui Medicine Co., Ltd.	Primary Extranodal Lymphoma\|DLBCL	June 1, 2022	Phase 2
NCT04593485	Fudan University	Malignant Melanoma	October 28, 2020	Phase 2
NCT04152889	RenJi Hospital	Gastric Cancer Stage III	April 14, 2020	Phase 2
NCT05214976	Jiangsu HengRui Medicine Co., Ltd.	Advanced Solid Tumors	April 30, 2022	Phase 2
NCT04181645	RenJi Hospital\|Jiangsu HengRui Medicine Co., Ltd.	Pancreatic Cancer Stage IV	June 29, 2019	Not Applicable
NCT05512481	Peking University Cancer Hospital & Institute	Melanoma\|Acral Melanoma\|Temozolomide\|Apatinib\|Camrelizumab\|Neoadjuvant\|Pathological Response	September 10, 2022	Phase 2
NCT04498689	Fudan University	Metastatic Pancreatic Cancer	August 1, 2019	Phase 2
NCT04510064	Fudan University	Metastatic Gastric Cancer\|Locally Advanced Gastric Adenocarcinoma	August 2020	Phase 2
NCT04506138	Zhejiang Cancer Hospital	Esophageal Squamous Cell Carcinoma	August 11, 2020	Phase 1\|Phase 2
NCT05043688	Zhigang Li\|Jiangsu HengRui Medicine Co., Ltd.\|Shanghai Chest Hospital	Locally Advanced Resectable Esophageal Squamous Cell Carcinoma	September 14, 2021	Phase 2
NCT05193292	Fudan University	Colorectal Neoplasms\|Intestinal Neoplasms	January 2022	Phase 2
NCT04297202	The First Affiliated Hospital with Nanjing Medical University\|Jiangsu Hengrui Pharmaceutical Co., Ltd.	Hepatocellular Carcinoma	December 1, 2019	Phase 2
NCT05550558	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Endometrial Cancer	November 1, 2022	Phase 2
NCT04044378	Peking University People´s Hospital\|Peking University Shougang Hospital\|Jiangsu HengRui Medicine Co., Ltd.	Effect of Drugs\|Progression\|Pediatric Cancer	August 15, 2019	Phase 1\|Phase 2
NCT03986515	Henan Cancer Hospital	Mucosal Melanoma\|Advanced Cancer\|Apatinib\|SHR-1210	June 4, 2019	Phase 2
NCT03827837	Jiangsu HengRui Medicine Co., Ltd.	Renal Cell Carcinoma\|Urothelial Carcinoma\|Cervical Cancer\|Ovarian Cancer Recurrent\|Endometrial Cancer	January 23, 2019	Phase 2
NCT05042375	Jiangsu HengRui Medicine Co., Ltd.	Non-small Cell Lung Cancer	September 8, 2022	Phase 3
NCT04490421	Fuzhou General Hospital	Lung Neoplasm\|Small Cell Lung Cancer\|PD-1 Inhibitors	August 1, 2020	Phase 3
NCT03912857	Sun Yat-sen University\|Jiangsu HengRui Medicine Co., Ltd.	Metastatic Colorectal Cancer	December 1, 2018	Phase 2
NCT04299581	Fudan University	Intrahepatic Cholangiocarcinoma	July 7, 2020	Phase 2
NCT05099848	Shandong Cancer Hospital and Institute\|Jiangsu HengRui Medicine Co., Ltd.	Hepatocellular Carcinoma	March 17, 2021	Phase 2
NCT04405154	West China Hospital	Head and Neck Neoplasms	June 1, 2020	Phase 2
NCT04974944	Sun Yat-sen University	Stage IVB Cervical Cancer\|Recurrent Cervical Cancer\|Persistent Cervical Cancer	July 30, 2021	Phase 2
NCT03816553	Sun Yat-sen University	Recurrent Cervical Carcinoma\|Metastatic Cervical Cancer	January 19, 2019	Phase 2
NCT03601598	Harbin Medical University\|Jiangsu HengRui Medicine Co., Ltd.	CRC\|HCC\|NSCLC	July 30, 2018	Phase 1\|Phase 2
NCT02738489	Jiangsu HengRui Medicine Co., Ltd.	Neoplasm	May 12, 2016	Phase 1
NCT04680988	Jiangsu HengRui Medicine Co., Ltd.	Recurrent or Metastatic Cervical Cancer	April 5, 2021	Phase 2
NCT04014101	Shanghai Zhongshan Hospital	Hepatocellular Carcinoma	June 1, 2019	Phase 2
NCT05342389	Sixth Affiliated Hospital, Sun Yat-sen University	Metastatic Gastric Adenocarcinoma\|Metastatic Gastroesophageal Junction Adenocarcinoma	May 1, 2022	Phase 2
NCT03134872	Jiangsu HengRui Medicine Co., Ltd.	Lung Neoplasms\|Carcinoma, Non-Small-Cell Lung\|Respiratory Tract Neoplasms\|Thoracic Neoplasms\|Lung Diseases\|Respiratory Tract Disease\|Neoplasms by Site\|Neoplasm, Bronchial\|Carcinoma, Bronchogenic	May 12, 2017	Phase 3
NCT04952571	Beijing Sanbo Brain Hospital	Recurrent Glioblastoma	May 1, 2021	Phase 2
NCT03878472	Qilu Hospital of Shandong University	Gastric Cancer	April 1, 2019	Phase 2
NCT04627012	Sun Yat-sen University\|Second Affiliated Hospital of Guangzhou Medical University	Hepatocellular Carcinoma\|Anti-PD1 Antibody\|Liver Diseases	January 1, 2018
NCT04443309	Peking Union Medical College Hospital\|Jiangsu HengRui Medicine Co., Ltd.	Hepatocellular Carcinoma	September 11, 2020	Phase 1\|Phase 2
NCT04303741	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Breast Cancer	March 25, 2020	Phase 2
NCT05564897	Zhejiang Cancer Hospital	Bladder Cancer	August 26, 2022	Phase 2
NCT03557411	Shandong Cancer Hospital and Institute\|Jiangsu HengRui Medicine Co., Ltd.	Non-Small-Cell Lung Cancer	July 9, 2018	Phase 2
NCT03155425	Jiangsu HengRui Medicine Co., Ltd.	Hodgkin Lymphoma, Adult	June 9, 2017	Phase 2
NCT04932187	Ruijin Hospital	Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi)	August 1, 2021	Phase 1
NCT04974827	Hunan Cancer Hospital\|Jiangsu HengRui Medicine Co., Ltd.	Cervical Cancer	May 20, 2021	Phase 2
NCT04346381	Jiangsu HengRui Medicine Co., Ltd.	Solid Tumor	June 5, 2020	Phase 2
NCT04067037	Henan Cancer Hospital	Classical Hodgkin Lymphoma	August 26, 2019	Phase 2
NCT03427827	Sun Yat-sen University	Nasopharyngeal Neoplasms	July 2, 2018	Phase 3
NCT04889768	Zhejiang Cancer Hospital	Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery	July 31, 2021	Not Applicable
NCT04781686	Zhou Fuxiang\|Hubei Cancer Hospital\|Henan Provincial People´s Hospital\|Huangshi Central Hospital, China\|Zhongnan Hospital	Metastatic Gastric Adenocarcinoma\|Metastatic Gastroesophageal Junction Adenocarcinoma	May 14, 2021	Phase 2
NCT04231552	Wuhan Union Hospital, China	Rectal Cancer\|Radiotherapy\|Immunotherapy	November 10, 2019	Phase 1\|Phase 2
NCT04830267	Chongqing University Cancer Hospital	Head and Neck Squamous Cell Carcinoma	March 1, 2021	Phase 2
NCT05549466	Sun Yat-sen University	Nasopharyngeal Carcinoma	September 20, 2022	Phase 2
NCT05202314	Beijing Chao Yang Hospital	Colorectal Cancer\|Neoadjuvant Chemotherapy\|Stent\|Obstruction\|Immunotherapy	December 12, 2021	Not Applicable
NCT03793725	Yanqiao Zhang\|Jiangsu HengRui Medicine Co., Ltd.\|Harbin Medical University	Hepatocellular Carcinoma	January 30, 2019	Phase 2
NCT05545436	Third Affiliated Hospital, Sun Yat-Sen University\|Jiangsu Hengrui Pharmaceutical Co., Ltd.	Locally Advanced Gastric Cancer	September 20, 2022	Phase 2
NCT04225364	Guangzhou Institute of Respiratory Disease\|BGI-Shenzhen\|Jiangsu HengRui Medicine Co., Ltd.	Esophageal Squamous Cell Carcinoma\|Immunotherapy	January 17, 2020	Phase 2
NCT04625803	Zhejiang University	Colon Cancer\|Neoadjuvant Therapy	January 4, 2021	Phase 2
NCT03092895	Jiangsu HengRui Medicine Co., Ltd.	Advanced Primary Liver Cancer\|Advanced Biliary Tract Carcinoma	April 27, 2017	Phase 2
NCT04202978	Zhongshan Hospital Xiamen University	Hepatic Metastasis of Colorectal Cancer	March 1, 2020	Phase 1\|Phase 2
NCT02742935	Jiangsu HengRui Medicine Co., Ltd.	Breastcancer\|Gastrointestinal Cancer	April 27, 2016	Phase 1
NCT05610332	Fujian Medical University	Locally Advanced Gastric Cancer	November 1, 2022	Phase 3
NCT04674956	RenJi Hospital	Pancreatic Cancer Stage IV\|Pancreatic Cancer Metastatic	January 1, 2021	Phase 3
NCT03363555	Jiangsu HengRui Medicine Co., Ltd.	Extranodal NK+T-cell Lymphoma, Nasal Type	May 29, 2018	Phase 2
NCT04415385	Zhejiang Cancer Hospital	Pancreatic Cancer	June 1, 2020	Phase 2
NCT03945604	Jiangsu HengRui Medicine Co., Ltd.	Triple Negative Breast Cancer	June 4, 2019	Phase 1
NCT04221516	Nanfang Hospital of Southern Medical University	Nasopharyngeal Carcinoma	February 1, 2020	Phase 2
NCT04239170	Peking University	Hodgkin Lymphoma	January 2020	Phase 2
NCT04440917	Shanghai Ninth People´s Hospital Affiliated to Shanghai Jiao Tong University	Head and Neck Squamous Cell Carcinoma	June 3, 2020	Phase 2
NCT03691090	Jiangsu HengRui Medicine Co., Ltd.	Advanced Esophageal Cancer	December 3, 2018	Phase 3
NCT04108013	Xuanwu Hospital, Beijing	Lung Cancer Stage II\|PD-1 Antibody\|Non-small Cell Lung Cancer	October 8, 2019	Phase 2
NCT03666728	Jiangsu HengRui Medicine Co., Ltd.	Lung Neoplasms	November 30, 2018	Phase 2
NCT05184946	The Second Affiliated Hospital of Shandong First Medical University	Gastric Cancer	October 9, 2021	Phase 2
NCT03736863	The First Affiliated Hospital of Zhengzhou University	Esophageal Cancer	December 5, 2019	Phase 2
NCT04174339	Fujian Cancer Hospital	Advanced Gastric Adenocarcinoma	December 10, 2019	Not Applicable
NCT04506242	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	NSCLC	September 15, 2020	Phase 2
NCT04805736	The First Affiliated Hospital with Nanjing Medical University\|Jiangsu HengRui Medicine Co., Ltd.	Breast Cancer	March 25, 2021	Phase 2
NCT04631757	Tianjin Medical University Cancer Institute and Hospital\|Jiangsu HengRui Medicine Co., Ltd.	Gastric Cancer	December 15, 2020	Phase 2
NCT05114707	Sun Yat-sen University	Nasal Cavity Cancer\|Paranasal Sinus Cancer\|Camrelizumab\|Induction Chemotherapy\|Intensity Modulated Radiotherapy\|Concurrent Chemotherapy	April 16, 2021	Phase 2
NCT04515615	Yu jiren\|First Affiliated Hospital of Zhejiang University	Gastric Cancer Stage III	September 9, 2020	Phase 2
NCT04399785	Xingchen Peng\|Jiangsu HengRui Medicine Co., Ltd.\|West China Hospital	Head and Neck Squamous Cell Carcinoma	June 1, 2020	Phase 2
NCT05019534	West China Hospital	BRAF V600E-mutated +MSS Metastatic Colorectal Cancer\|Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody	August 15, 2021	Phase 1
NCT04616040	Peking University	Esophageal Cancer	December 1, 2020
NCT05088057	Aiping Shi\|Jilin University	Triple Negative Breast Cancer (TNBC)	September 20, 2021	Phase 2
NCT05410847	Hebei Medical University	Gastric Cancer	June 30, 2022	Phase 2
NCT04609176	Peking University\|Jiangsu HengRui Medicine Co., Ltd.	Gastric Cancer	October 22, 2020	Phase 2
NCT04355858	Fudan University	Breast Cancer\|Metastatic Cancer	May 1, 2020	Phase 2
NCT03187314	Hangzhou Cancer Hospital\|Jiangsu HengRui Medicine Co., Ltd.	Esophageal Neoplasms\|Esophageal Diseases\|Esophageal Squamous Cell Carcinoma	June 14, 2017	Phase 2
NCT04649476	Hospital of Stomatology, Wuhan University\|Jiangsu HengRui Medicine Co., Ltd.	Oral Squamous Cell Carcinoma	March 22, 2021	Phase 2
NCT04888429	Qian Chu\|Jiangsu HengRui Medicine Co., Ltd.\|Tongji Hospital	Sarcomatoid Carcinoma of Lung	July 19, 2021	Phase 2
NCT05322499	Zhejiang Cancer Hospital	Stage IV Esophagus Squamous Cell Carcinoma	April 15, 2022	Phase 2
NCT04642664	Peking Union Medical College Hospital	Biliary Tract Cancer\|Cholangiocarcinoma\|Biomarker\|Hepatobiliary Neoplasm	December 1, 2018	Phase 2
NCT04564313	Third Affiliated Hospital, Sun Yat-Sen University	Hepatocellular Carcinoma\|Liver Transplantation	September 21, 2020	Phase 1
NCT04530227	Tianjin Medical University Cancer Institute and Hospital	Early Stage Non-small Cell Lung Cancer	September 25, 2020	Phase 2
NCT04654403	The First Affiliated Hospital of Zhengzhou University	Esophageal Cancer	January 1, 2022	Not Applicable
NCT04866381	Tianjin Medical University Cancer Institute and Hospital	Esophageal Squamous Cell Carcinoma\|Progression to PD-1 Antibody	April 2021	Phase 2
NCT04286711	China Medical University, China	Advanced Gastric Cancer	March 2020	Phase 1\|Phase 2
NCT04342910	Jiangsu HengRui Medicine Co., Ltd.	Gastric Cancer	September 21, 2020	Phase 3
NCT04454905	Sun Yat-sen University\|Jiangsu HengRui Medicine Co., Ltd.	Intrahepatic Cholangiocarcinoma	August 1, 2020	Phase 2
NCT05053802	Shanghai Pulmonary Hospital, Shanghai, China	Multiple Primary Lung Cancer	March 21, 2021	Phase 2
NCT05051865	Peking University Cancer Hospital & Institute	Melanoma	October 9, 2021	Phase 2
NCT04337606	Chinese PLA General Hospital	Non Hodgkin Lymphoma	April 4, 2020	Phase 1\|Phase 2
NCT03764293	Jiangsu HengRui Medicine Co., Ltd.	Locally Advanced or Metastatic and Unresectable HCC	June 10, 2019	Phase 3
NCT03671265	Tianjin Medical University Cancer Institute and Hospital\|Jiangsu HengRui Medicine Co., Ltd.	Esophageal Cancer	September 17, 2018	Not Applicable
NCT05176002	Fujian Medical University Union Hospital	Esophageal Neoplasm\|Immunotherapy\|Radiotherapy	September 23, 2021	Phase 1\|Phase 2
NCT03871855	Jiangsu HengRui Medicine Co., Ltd.	Advanced Solid Tumor	April 2019	Phase 1
NCT04487704	First Affiliated Hospital Xi´an Jiaotong University	Advanced Hepatocellular Carcinoma	April 7, 2020	Not Applicable
NCT04560127	Peking Union Medical College Hospital	Radioactive Iodine-refractory Differentiated Thyroid Cancer	September 23, 2020	Phase 2
NCT03085069	Jiangsu HengRui Medicine Co., Ltd.	Lung Neoplasms\|Carcinoma, Non-Small-Cell Lung\|Respiratory Tract Neoplasms Nec\|Lung Disease\|Respiratory Tract Disease\|Neoplasm, Bronchial\|Carcinoma, Bronchogenic	June 9, 2017	Phase 2
NCT05003700	Nanfang Hospital of Southern Medical University	Hepatocellular Carcinoma	April 20, 2021	Phase 2
NCT04156698	Eye & ENT Hospital of Fudan University	Hypopharyngeal Carcinoma\|Immunotherapy\|Chemotherapy	May 21, 2020	Phase 2
NCT03755115	Henan Cancer Hospital\|Jiangsu HengRui Medicine Co., Ltd.	Small Cell Lung Cancer Extensive Stage	February 1, 2019	Phase 2
NCT04068974	Peking Union Medical College Hospital	Recurrent Platinum-resistant Ovarian Cancer	October 28, 2019	Phase 2
NCT04420130	Yanqiao Zhang\|Harbin Medical University	Pancreatic Cancer\|Liver Metastasis	August 1, 2020	Not Applicable
NCT04512417	Zhejiang Cancer Hospital	Esophageal Cancer	August 31, 2020	Phase 2
NCT04303130	Peking University Cancer Hospital & Institute\|Peking University First Hospital\|Peking University Third Hospital\|Beijing Shijitan Hospital, Capital Medical University\|Chinese PLA General Hospital\|Peking Union Medical College Hospital\|Peking University People´s Hospital	Non-small Cell Lung Cancer	December 31, 2019	Phase 2
NCT03083041	Jiangsu HengRui Medicine Co., Ltd.	Carcinoma, Non-Small-Cell Lung	March 22, 2017	Phase 2
NCT03250962	Chinese PLA General Hospital	Hodgkin Lymphoma	September 11, 2017	Phase 2
NCT05524974	Fujian Medical University	Locally Advanced Gastric Cancer	September 1, 2022	Phase 2
NCT04850040	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Hepatocellular Carcinoma Resectable	May 6, 2021	Phase 2
NCT04790539	Shanghai Pulmonary Hospital, Shanghai, China	Extensive Stage Small Cell Lung Cancer	April 1, 2021	Phase 2
NCT04586088	Sun Yat-sen University	Nasopharyngeal Carcinoma\|Recurrent Nasopharyngeal Carcinoma\|Metastatic Nasopharyngeal Carcinoma\|Chemotherapy Effect\|Immunotherapy\|Molecular Targeted Therapy	May 5, 2020	Phase 2
NCT04683198	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Small-cell Lung Cancer	April 1, 2021	Phase 2
NCT04541251	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University\|Guangdong Provincial People´s Hospital\|Third Affiliated Hospital, Sun Yat-Sen University	Lung Cancer, Non-small Cell\|Artificial Intelligence	August 1, 2020	Phase 2
NCT04797507	Peking Union Medical College Hospital	SHR-1210\|Anlotinib\|Advanced Esophageal Squamous Cell Cancer	March 2021	Phase 2
NCT03631615	Shanghai Zhongshan Hospital\|Jiangsu HengRui Medicine Co., Ltd.	Gastric Adenocarcinoma	August 20, 2018	Phase 2
NCT05171309	Nanfang Hospital of Southern Medical University	Hepatocellular Carcinoma	January 1, 2021	Phase 2
NCT05438706	Fudan University	Triple-negative Breast Cancer	July 10, 2022	Phase 2
NCT05166239	Peking University	Hepatocellular Carcinoma\|Portal Vein Thrombosis	January 2022	Phase 2
NCT04447274	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Sarcoma	July 1, 2020	Phase 2
NCT03711279	Jiangsu HengRui Medicine Co., Ltd.	Sarcoma	November 21, 2018	Phase 2
NCT04203485	Jiangsu HengRui Medicine Co., Ltd.	PD-L1 Positive Non-small Cell Lung Cancer	June 15, 2020	Phase 3
NCT03955354	Peking University Cancer Hospital & Institute	Melanoma	March 5, 2019	Phase 2
NCT05290935	Lei Li\|Peking Union Medical College Hospital	Recurrent Cervical Carcinoma\|Persistent Advanced Cervical Carcinoma\|Chemotherapy\|Immune Checkpoint Inhibitors\|Anti-PD-1 Antibody\|Albumin-bound Paclitaxel	March 13, 2022	Phase 2
NCT03777124	Jiangsu HengRui Medicine Co., Ltd.\|Shanghai Chest Hospital	NSCLC Stage IV\|KRAS Gene Mutation\|PD-1 Antibody\|Chemotherapy Effect	February 2019	Phase 2
NCT03605706	Jiangsu HengRui Medicine Co., Ltd.	Advanced Hepatocellular Carcinoma	May 31, 2019	Phase 3
NCT04548271	Sun Yat-sen University	Nasopharyngeal Carcinoma	September 2020	Phase 2
NCT03701022	Peking University	NK+T-cell Lymphoma	October 20, 2018	Phase 2
NCT04508686	Ruijin Hospital	Advanced Cervical Cancer	August 1, 2020	Phase 1
NCT05069857	Shanghai Jiao Tong University School of Medicine	Oral Squamous Cell Carcinoma\|Neoadjvant Therapy\|Anti-PD-1\|Anti-VEGFR	September 1, 2021	Phase 2
NCT03987698	Tianjin Medical University Cancer Institute and Hospital	Renal Cell Carcinoma\|Clear Cell Renal Cell Carcinoma	June 1, 2019	Phase 2
NCT04510818	Ruijin Hospital	Head and Neck Cancer\|Esophageal Squamous Cancer	August 1, 2020	Phase 1
NCT04367025	Chinese PLA General Hospital	Gastric Cancer	May 2020	Phase 2
NCT04481763	Jiangxi Provincial Cancer Hospital	Triple-Negative Breast Cancer	July 14, 2020	Phase 1\|Phase 2

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References